Please Wait
Applying Filters...

End Use API: CAS 865758-96-9

Filters
×

filter

Cangzhou Senary Chemical Science-tech Co., Ltd

Mehta API Pvt. Ltd.,

Waterstone Pharmaceuticals Inc.

API and Contract Manufacturer.

CAS Number

865758-96-9

End Use API

ALOGLIPTIN BENZOATE

Supporting Information

View All Icon

About the Company

Mehta API is EU-GMP by Swiss-Medic (PICS), ED...

Mehta API is EU-GMP by Swiss-Medic (PICS), EDQM, TGA, WHO -GMP certified & PMDA US-FDA approvable facility with land area 26,580 sq. mt. It is a research driven organization, focusing on development, using green chemistry, manufacturing and marketing of API’s- multi step, highly complex, potent, chiral & semi-synthetic, Advance intermediates, specialty chemicals and building blocks. We are committed to Excellence in Product Quality and adherence to agreed delivery schedule. We export to about 20 countries including Regulated Markets spanning all 6 continents, developing technology and translating to production and delivery to customers.

Request an Update of Your Company Information, Events & Sales Content

CAS Number

865758-96-9

End Use API

ALOGLIPTIN BENZOATE

Supporting Information

View All Icon

About the Company

Founded in 2003, Senary Chem is one of the Ke...

Founded in 2003, Senary Chem is one of the Key High-Tech Enterprises of National Torch Plan. Senary located in National Cangzhou Lingang Economic and Technological Development Zone,Cangzhou City,Hebei Province. Senary cover an area of 67,000 square meters, and 300 professionals work there. Senary R&D organization recognized as the Hebei Provincial Engineering Technology Center is comprised of two R & D centers in Tianjin and Cangzhou, and it employs 80 experienced scientists in total. Senary focus on the development, production and sales of advanced pharmaceutical intermediates. Especially, Senary has leading technology and manufacturing capacity for diabetes drug intermediates. All intermediates of DPP4 and SGLT2 class drugs on market have been commercialized production. Senary has 150 sets of 50 ~ 8000L reactor with annual production capacity of 1,000 tons, which can handle both low and high temperature reactions within -100 ~ 240 ℃ range, all kinds of catalytic reactions within 0 ~ 5MPa pressure, and moisture and/or oxygen sensitive reactions. Senary also has expertise in chiral synthesis with leading technologies. The advanced sewage treatment system at Senery has processing capacity of 600 tons daily. Senary has an excellent team that has rich quality management experience.We have established a set of normative and perfect quality managment system,monitoring the whole process of risk assessment,R&D,transfer from pilot scale to commercial production,manufacturing,analysis and sales service. Senary will continue to dedicate on the field of pharmaceutical intermediates to provide the best service for domestic and foreign API pharmaceutical companies with high quality and timely supply of products.

Request an Update of Your Company Information, Events & Sales Content

CAS Number

865758-96-9

End Use API

ALOGLIPTIN BENZOATE

Supporting Information

View All Icon

About the Company

Waterstone is an international pharmaceutical...

Waterstone is an international pharmaceutical company with its main operations in China. The company is focused in discovery, development and commercialization of innovative drugs for the treatment of liver and gastrointestinal diseases. With venture capital investments from internationally well-known firms such as BAR Capital, CID Group, Orbimed, and Acorn Camps, the company has established fully integrated capabilities from R&D, API & Finished Drug Product manufacturing to sales/marketing. The company has a strong management team with cross-border experience and advisors with expertise in drug discovery, regulatory, and GMP manufacturing. On top of the forty marked drugs in China, the company has also built a rich pipeline including Drug Master Files with U.S. FDA , candidates in phase II/III clinical tries with cFDA, and several novel preclinical stage antiviral and oncology candidates

PharmaCompass >>

First
Previous
Next
Last